The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease by MARIN-NETO, J Antonio et al.
319
online | memorias.ioc.fiocruz.br
Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 104(Suppl. I): 319-324, 2009
The BENEFIT trial: testing the hypothesis that trypanocidal therapy is 
beneficial for patients with chronic Chagas heart disease
J Antonio Marin-Neto1/+, Anis Rassi Jr2, Alvaro Avezum Jr3, Antonio C Mattos3, Anis Rassi2
1Divisão de Cardiologia, Departamento de Medicina Interna, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, 
Ribeirão Preto, SP, Brasil 2Hospital Anis Rassi, Goiânia, GO, Brasil 3Instituto Dante Pazzanese de Cardiologia, São Paulo, SP, Brasil
Among the pathophysiological derangements operating in the chronic phase of Chagas disease, parasite persis-
tence is likely to constitute the main mechanism of myocardial injury in patients with chronic chagasic cardiomyo-
pathy. The presence of Trypanosoma cruzi in the heart causes a low-grade, but relentless, inflammatory process 
and induces myocardial autoimmune injury. These facts suggest that trypanocidal therapy may positively impact 
the clinical course of patients with chronic Chagas heart disease. However, the experimental and clinical evidence 
currently available is insufficient to support the routine use of etiologic treatment in these patients. The BENEFIT 
project - Benznidazole Evaluation for Interrupting Trypanosomiasis - is an international, multicenter, double-blind, 
placebo-controlled trial of trypanocidal treatment with benznidazole in patients with chronic Chagas heart disease. 
This project is actually comprised of two studies. The pilot study investigates whether etiologic treatment signifi-
cantly reduces parasite burden, as assessed by polymerase chain reaction-based techniques and also determines 
the safety and tolerability profile of the trypanocidal drug in this type of chagasic population. The full-scale study 
determines whether antitrypanosomal therapy with benznidazole reduces mortality and other major cardiovascular 
clinical outcomes in patients with chronic Chagas heart disease. 
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Unfortunately, one century after its discovery (Cha-
gas 1909), Chagas disease still affects millions of poor 
people in several Latin American countries and is a 
leading cause of sudden death, severe cardiac arrhyth-
mias and intractable heart failure (Dias et al. 2008). In 
addition, the disease cannot be prevented by vaccination 
or, in many situations, be reliably cured by antiparasitic 
drugs. Various epidemiological features of the disease re-
quire appropriate evaluation, including recent outbreaks 
of acute infection in the Amazon Region (Coura 2007). 
Long after the initial phase, the only period when the 
etiologic agent is readily found, clinical complications of 
the chronic phase appear in at least 30-40% of infected 
people. So far, there is no way to predict which patients 
will develop these chronic complications (Dias 1989), 
nor do we understand the mechanisms leading to many 
of them, including myocardial damage (Marin-Neto et al. 
2007). One possibility is that autonomic nervous system 
disturbances (Köberle 1968) cause ischemic myocardial 
insult or trigger ventricular arrhythmias, both of which 
can cause sudden death (Amorim & Marin-Neto 1995). 
Also, regional perfusion disturbances and abnormal con-
trol of the coronary microcirculation are likely to play at 
least an ancillary role in myocardial fibre destruction, 
which leads to fibrotic replacement (Rossi 1990, Marin-
Neto et al. 1992). Myocardial autoimmune inflamma-
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tion also occurs in both experimental and clinical cases 
of chronic Chagas cardiomyopathy (Cunha-Neto et al. 
2006, Kierszenbaum 2007). Studies have shown that 
the low-grade, incessant myocarditis seen in the chronic 
phase of Chagas disease is related to parasite persistence 
(Bellotti et al. 1996, Tarleton 2003) and much of the im-
mune-mediated myocardial inflammation may also be 
parasite-driven. Therefore, eliminating the parasite, or 
at least reducing its burden, may favourably impact the 
natural history of chronic Chagas disease. 
Trypanocidal drugs used in Chagas disease
Chagas disease continues to be a rather neglected 
morbid entity, as illustrated by the fact that for more than 
three decades, only two drugs, nifurtimox and benznida-
zole, have been available to effectively treat Trypano-
soma cruzi. Nifurtimox, a nitrofuran derivative (Lampit, 
Bayer 2503, Leverkusen, Germany), has been extensive-
ly used for over three decades, but is currently not avail-
able in several countries, including Brazil. Benznidazole 
(LAFEPE, Recife, Brazil), a nitroimidazole derivative, 
has also been widely used as an effective agent for anti-
parasitic therapy in cases of acute or sub-acute Chagas 
disease, including transfusion and laboratory-acquired 
disease and reactivation of infection in transplanted and 
other immunosuppressed patients.
Trypanocidal therapy in acute Chagas disease 
In the acute stages of Chagas infection, nifurtimox 
reduces the severity and duration of the illness and may 
possibly reduce mortality. Parasitological cure (per-
manent negative xenodiagnosis and serology) occurs 
in about 70% of treated patients. The main drawback 
of nifurtimox therapy is the high incidence of side ef-
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fects, which are reported in up to 40% of patients. Side 
effects with nifurtimox usually include gastrointestinal 
complaints, such as nausea, vomiting, abdominal pain, 
weight loss and severe anorexia. Neurologic adverse ef-
fects may also occur and include restlessness, paresthe-
sias, twitching, insomnia and seizures. These symptoms 
generally resolve when the dosage is reduced or therapy 
is discontinued. Therapy with benznidazole has a simi-
lar efficacy profile to nifurtimox, with the advantage of 
a lower side-effect rate. Treatment with benznidazole in 
cases of acute Chagas disease produces long-term para-
sitologic cure in approximately 70% of patients. In one 
study, 43 patients treated in the acute phase of Chagas 
disease with benznidazole or nifurtimox were followed 
for several years (Rassi et al. 2000). The incidence of 
chronic clinical manifestations of the disease was higher 
in patients whose serology was positive after treatment 
(36%) compared to those patients with long-term nega-
tive serology (7%).
No randomised studies have examined the effect of 
benznidazole on significant clinical long term outcomes 
of patients treated during the acute phase of Chagas dis-
ease. Despite the lack of such evidence, it is generally 
accepted that antiparasitic therapy should be adminis-
tered to all patients diagnosed with acute Chagas dis-
ease, regardless of the mechanism of infection. Further-
more, this treatment should also be initiated in all cases 
of disease reactivation in chronic patients (Rassi et al. 
2000, Bern et al. 2007).
Trypanocidal therapy in chronic Chagas disease
The role of antiparasitic treatment in the chronic 
phase of Chagas disease is more controversial, as evi-
dence from studies, either using experimental models 
of the disease or following chronic Chagas patients, is 
scarce. Data suggest that from a serological and parasito-
logical standpoint, the cure rates of treatment are highly 
variable in the chronic phase of the disease and depend 
on the timing of treatment, with higher rates seen in 
those treated earlier in the disease. These data also in-
dicate that following the trypanocidal therapy, there is a 
gradual decrease in the serological titres of antitrypano-
soma antibodies, and that treatment failure may some-
times manifest, even decades after persistently negative 
xenodiagnostic tests. 
Evidence of benefit with trypanocidal therapy in ex-
perimental models of chronic Chagas disease 
There is some evidence that etiologic treatment in an-
imals infected with the T. cruzi may attenuate the course 
of myocarditis in the chronic phase of Chagas disease. 
One study showed that in mice chronically infected with 
various strains of T. cruzi, treatment with benznidazole 
or nifurtimox had significantly less myocardial damage, 
as assessed by histopathology, than untreated infected 
mice (Andrade et al. 1991). 
A more recent study demonstrated several beneficial 
effects of benznidazole treatment in mice chronically 
infected with the Colombian T. cruzi. Compared to un-
treated mice, the hearts of treated mice had less parasit-
ism and myocarditis. Treatment also led to less cardiac 
conduction disturbances and ventricular extrasystoles 
in the electrocardiogram (ECG) of treated animals, as 
well as lower serum levels of antibodies against T. cruzi 
antigens (epimastigote extract, P2β, and trans-sialidase). 
Decreased antibodies against peptides of the second 
extracellular loops of β1-adrenergic and M2-muscarinic 
cardiac receptors in benznidazole-treated mice were also 
seen. The investigators concluded that etiologic treatment 
in the chronic phase of infection prevented the develop-
ment of severe chronic cardiomyopathy, despite the lack 
of complete parasite eradication (Garcia et al. 2005). 
Evidence of benefit with trypanocidal therapy in hu-
man chronic Chagas disease 
While there have been both observational and ran-
domised controlled studies, no conclusions can be de-
finitively drawn from these studies. Overall, clinically 
significant endpoints were included in several nonran-
domised studies, but the conclusions were hindered by 
their observational design. Conversely, the randomised 
studies failed to include hard endpoints, limiting their 
clinical relevance.
Evidence from non-randomised clinical trials
Several nonrandomised studies suggested that etio-
logic treatment led to negative serological tests and pre-
vented clinical and electrocardiographic changes associ-
ated with disease progression (Macedo & Silveira 1987, 
Miranda et al. 1994, Viotti et al. 1994, 2006, Fragata Filho 
et al. 1995, Fabbro et al. 2000, Gallerano & Sosa 2001).
However, other studies yielded contradictory results, 
concluding that the etiologic treatment in the chronic 
phase of Chagas disease failed to exterminate the para-
site, halt the progress of the disease, or prevent its com-
plications (Ianni et al. 1993, Catalioti & Acquatella 1999, 
Lauria-Pires et al. 2000, Britto et al. 2001). 
Regardless of the results, the evidence from these 
nonrandomised studies is weak, as shown in the best of 
these investigations the 2006 paper by Viotti et al. In 
this trial, 598 of the 1,968 screened chronic chagasic pa-
tients were unblindly and non-randomly assigned to no 
treatment or to treatment with 5 mg/kg per day of ben-
znidazole for 30 days. Nearly 60 patients in each group 
were lost to follow-up. In those remaining in the trial, 
after a median follow-up period of approximately 11.5 
years, conversion to negative results on serologic tests 
was more frequent in treated patients than in untreated 
patients [32 of 218 (15%) vs. 12 of 212 (6%); adjusted 
hazard ratio, 2.1 (CI, 1.06-4.06); p = 0.034]. Also, fewer 
treated patients showed progression of disease [12 of 283 
(4%) vs. 40 of 283 (14%); adjusted hazard ratio, 0.24 (95% 
CI, 0.10-0.59); p = 0.002] or developed abnormalities on 
electrocardiography [15 of 283 (5%) vs. 45 of 283 (16%); 
adjusted hazard ratio, 0.27 (CI, 0.13-0.57); p = 0.001) 
compared to untreated patients (Viotti et al. 2006).
Before the publication of that last trial, two inde-
pendent analyses of pooled data from several of these 
observational studies concluded that there was insuffi-
cient evidence to support the routine use of trypanocidal 
therapy in patients with chronic Chagas disease (Villar 
2002, Reyes & Vallejo 2005). 
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Evidence from randomised clinical trials
After a systematic review of the literature, we found 
only five randomised trials investigating the effects of 
trypanocidal therapy in chronic Chagasic patients (Vil-
lar et al. 2002). In all, there were 756 patients whose 
data were pooled and used for a meta analysis. Unfortu-
nately, only three of these studies used benznidazole or 
nifurtimox as trypanocidal agents (Andrade et al. 1996, 
Coura et al. 1997, Sosa Estani et al. 1998), while the 
other studies used ineffective drugs, such as allopurinol, 
skewing their results (Lauria-Pires et al. 1988, Rassi et 
al. 2007). Furthermore, none of these studies used de-
finitive hard clinical endpoints. Nevertheless, after a 
follow-up period ranging from 1-4 years, several indi-
ces showed significantly less parasite burden in treated 
patients compared to untreated patients. Negative sero-
conversion occurred in 61 of the 102 treated patients, 
compared to only six of the 98 untreated patients [OR 
(odds ratio) = 10.91, p < 0.01). Forty of the 42 treated pa-
tients (95%) also had a negative xenodiagnosis compared 
to only 21 of the 43 untreated patients (48%; OR = 5.37, 
p < 0.01). Additionally, when looking at the reduction 
of antibody titres against the T. cruzi, the OR compar-
ing the treated vs. the non-treated groups was 0.54 (p < 
0.01). Finally, ECG changes - the only clinical endpoint 
reported - were seen in fewer treated patients (2/99) than 
non-treated patients (5/99) (Villar et al. 2002)
These results are encouraging, as they suggest that 
patients with chronic Chagas disease benefit from try-
panocidal treatment, at least in terms of parasite burden 
reduction. However, the failure of trypanocidal drugs in 
treating patients in the chronic phase of Chagas disease 
could be better diagnosed if more sensitive methods for 
detection, such as PCR, were used (Britto et al. 1995, 
Galvão et al. 2003).
Overall, the decision to prescribe anti-parasite treat-
ment to patients with chronic Chagas disease is left to 
the individual physician, as there is no definitive evi-
dence arguing for or against such therapy. This decision 
is especially important when the patient already exhibits 
symptoms or signs of cardiomyopathy. The physician 
opting not to offer trypanocidal therapy is running the 
risk of committing the type II or β-error. Conversely, 
adopting the etiologic therapy alternative, the physician 
runs the risk of type I or α-error. The only way to resolve 
this dilemma is to directly examine the effect of anti-
parasitic treatment on the clinical outcome of chronic 
Chagas disease. Therefore, the BENEFIT trial - Ben-
znidazole Evaluation for Interrupting Trypanosomiasis 
- was undertaken to test the hypothesis that eliminating 
the etiologic agent or at least reducing the parasite bur-
den, may favourably impact the clinical evolution of pa-
tients with Chagas-induced cardiomyopathy. The design 
and rationale of this study has been recently published 
(Marin-Neto et al. 2008).
The BENEFIT project
Except for the initial period of drug trial adminis-
tration, during which the patients will be double blindly 
treated with the active drug or placebo, the protocol is 
designed to not interference with the management of the 
clinical manifestations of Chagas-induced cardiomyopa-
thy, including arrhythmia, heart failure or thromboembo-
lism. The two parallel treatment groups are composed of 
both men and women aged 18-75 years. The women were 
not pregnant and had no childbearing potential. Broad 
inclusion indications, with few exclusion criteria, were 
selected to assure a fully representative sample of the 
many types of patients with chronic Chagas cardiomyo-
pathy. The trial will include two consecutive phases.
The BENEFIT pilot study
The primary objective of the BENEFIT pilot study 
will be to determine the efficacy of benznidazole in 
reducing parasite burden in patients with chronic Cha-
gas cardiomyopathy, as well as assess the drug’s safety 
and tolerability. 
The co-primary efficacy outcomes of the pilot study 
are negative T. cruzi detection by PCR and mean para-
site load reduction as assessed by the concentration of T. 
cruzi/mL of blood by real-time PCR. 
There are three secondary outcomes for the BEN-
EFIT pilot study: (i) safety and tolerability of benznida-
zole, as determined by the incidence of adverse effects 
reported in each group and the number who complete 
the treatment period at full dose. The target for the lat-
ter outcome is 85% completion of therapy in the treated 
group at the end of the treatment period. Safety and 
tolerability assessment will determine the incidence of 
minor symptoms such as malaise, headache, gastric or 
enteric intolerance, and more significant adverse effects, 
such as dermatitis, lowering of white blood cell counts 
and peripheral neuropathy. Toxic effects will also be as-
sessed through liver and renal function tests [aspartate 
amino-transferase (AST), alanine amino-transferase 
(ALT), creatinine] measured before initiation and after 
completion of treatment. The number of leucocytes will 
be assessed after three weeks of treatment and after com-
pletion of therapy. The incidence of drug discontinuation 
will be recorded in the two experimental groups [brief 
(< 1 week) interruption is allowed for minor intoler-
ance]. The only strict criteria for permanent discontinu-
ation of benznidazole study medication are: significant 
leucopoenia (< 2,500), peripheral neuropathy or severe 
allergic dermopathy (not responding to corticosteroids). 
In other situations, discontinuation of the study drug 
will be discouraged as much as possible. Study drug 
accountability, as well as all pre-specified concomi-
tant medications, will be appropriately recorded at each 
scheduled visit; (ii) long-term feasibility, which will be 
assessed by patient enrolment and patient completion of 
follow-up. The target for completeness of follow-up at 
two years is 95% and (iii) composite of clinically signifi-
cant outcomes, which include death, cardiac transplanta-
tion, resuscitated cardiac arrest, documented sustained 
ventricular tachycardia (SVT) requiring cardioversion, 
new development of symptomatic congestive heart fail-
ure, implantation of pacemaker or cardiac defibrillator, 
stroke or any other systemic of pulmonary thromboem-
bolic event in patients with no prior thromboembolism.
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The BENEFIT full-scale trial
The primary objective of the full-scale trial is to 
evaluate whether antitrypanosomal therapy with ben-
znidazole reduces mortality and major cardiovascular 
clinical outcomes in patients with chronic Chagas heart 
disease. The primary outcome of the BENEFIT full-scale 
is a composite of major cardiovascular outcomes defined 
as the first occurrence of death, resuscitated cardiac ar-
rest, SVT, symptomatic heart failure, pacemaker or car-
diac defibrillator insertion, stroke or other systemic or 
pulmonary thromboembolic event. The secondary objec-
tive of the BENEFIT full-scale trial is to determine if the 
etiologic treatment reverses or halts objective evidence 
of left ventricular (LV) function deterioration and ECG-
changes, or reduces symptoms and parasite burden. The 
secondary outcomes for the BENEFIT full-scale trial are: 
(i) new development of any of the following echo chang-
es: segmental wall motion abnormalities (including ven-
tricular aneurysm), reduction in LV ejection fraction > 
5%, increase in LV diastolic diameter (LVDD) > 5.0 mm 
compared with baseline; (ii) new 12-lead ECG alterations; 
(iii) progression of New York Heart Association (NYHA) 
functional class by at least one category and (iv) reduc-
tion in parasite burden as assessed by real-time PCR.
A number of substudies will be conducted as part of 
the BENEFIT program and will address other issues of 
parasite pathogenicity, their relationship with geographi-
cal location and describe the clinical course in popula-
tions that are infected by different strains of the parasite 
such as T. cruzi I and II (Prata 2001).
Patient eligibility criteria
Patients with confirmed Chagas disease, i.e., any 
combination of at least two positive serological tests for 
Chagas disease (indirect immunofluorescence, indirect 
hemagglutination or ELISA), aged ≥ 18 years and ≤ 75 
years are eligible to participate in the BENEFIT trials if 
they have evidence of cardiomyopathy based on one or 
more of the following criteria: (i) abnormal ECG (at least 
2 of the following changes): right bundle branch block; 
left bundle branch block; left anterior fascicular block; 
left posterior fascicular block; ventricular premature 
beats; first degree atrioventricular (AV) block > 220 m 
in the absence of drugs that slow AV conduction; Mobitz 
type I AV block in the absence of drugs that slow AV 
conduction; sinus bradycardia < 50 bpm or sinus pauses 
> 3 s in the absence of sinus node-blocking drugs; prima-
ry ST-T changes; abnormal Q waves; low voltage of QRS 
or (ii) atrial fibrillation or abnormal ECG (only 1 of the 
following changes is necessary: Mobitz type II advanced 
or (iii) third degree AV block and cardiac pacemaker or 
(iii) implanted automatic defibrillator or (iv) increased 
cardiothoracic ratio (> 0.50) or (v) complex ventricular 
arrhythmias (multiform > 10 h, couplets or non-SVT  on 
24 h ambulatory ECG monitoring or (vi) evidence of re-
gional wall-motion abnormality or reduced (< 50%) glo-
bal LV systolic function (2D-Echo, radionuclide angiog-
raphy, contrast ventriculography) or increased LV end 
diastolic diameter (> 55 mm) on 2D-Echo. 
A few exclusion criteria are applicable to enrolling 
patients: NYHA heart failure class IV or decompensated 
heart failure; evidence of concomitant coronary artery 
disease or other aetiology of dilated cardiomyopathy; 
previous treatment with trypanocidal agents or an ac-
cepted indication for antiparasitic therapy (e.g. reactiva-
tion of Chagas infection due to immunosuppression by 
several diseases or treatment with steroids); inability to 
comply with follow-up; history of severe alcohol abuse 
within two years; known chronic renal insufficiency 
(serum creatinine > 2.5 mg/dL or 200 μmoL) or hepatic 
insufficiency (AST/ALT > 3 x normal); pregnancy or 
breast feeding; megaesophagus with severe swallowing 
impairment; or other severe disease significantly cur-
tailing life expectancy.
Ethics and patient confidentiality
All the procedures used are in accordance with the 
ethical standards of the responsible committees on hu-
man experimentation (institutional for each centre and 
regional for each country involved) and with the Hel-
sinki Declaration of 1975, as revised in 1983).
Sample sizes
Six hundred patients with positive parasite detection 
by PCR at baseline will be recruited in the pilot trial. 
A spontaneous negativisation rate of 20-30% is expect-
ed in the patients receiving placebo (Britto et al. 1995, 
2001, Galvão et al. 2003),  The sample size calculations 
were done with two possible treatment effects, a 50% 
and a 100% relative increase in negativisation for the 
two expected rates of spontaneous negativisation (20% 
and 30%). With a 2-sided α = 0.04 in this analysis, there 
is excellent power to detect a doubling of negativisation 
(increase of 100%) and reasonable power to detect a 50% 
increase in negativisation within the range of spontane-
ous negativisation expected in the control group. The pi-
lot study is well-powered to detect a reduction in mean 
parasite load between the two groups after two years, 
and a relative reduction of 25% in parasite load (or an 
absolute reduction of 6.5) with benznidazole.
Three thousand patients are needed for the full-
scale trial (1,500 per group). This represents the mini-
mum number required to detect a 26% relative risk in 
the risk of the composite end point (death, resuscitated 
cardiac arrest, cardiac transplantation, development of 
new heart failure, life-threatening nonfatal arrhythmias, 
thromboembolism and need for pacemaker or defibril-
lator implantation) with 90% power. This calculation 
assumes a yearly event rate of 8% in the control group 
and 4-6 years of follow-up (at 2-sided α = 0.05) (Rassi 
et al. 2006). The reported rates of noncompliance with 
benznidazole are around 17% and we expect a loss to 
follow-up of 3%.
Treatment regimen and follow-up
The first 1,500 patients were randomly assigned to 
placebo or benznidazole at 5 mg/kg per day for 60 days, 
with an upper limit of dosing at 400 mg per day (cor-
responding to a body weight of 80 kg). For the last 1,500 
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patients, due to logistic reasons, the dosing policy was 
changed. While keeping the rate of 5 mg/kg of body 
weight and the total dose to be taken, we will limit the 
maximum daily dose of 300 mg per day and establish a 
direct relationship between the number of days of treat-
ment and the body weight. Thus, a 60 kg patient will take 
300 mg for 60 days, a 80 kg patient with will take 300 
mg per day for 80 days and a 40 kg patient will take 300 
mg per day for 40 days.
Randomisation is always at 1:1, with stratification ac-
cording to centre, using a random-block system. Sched-
uled follow-up visits will occur at 11 days after initiation 
of therapy, 21 days, and at the completion of treatment. 
The next visits will be at six months and then annually 
until a minimum of four and a maximum of six years 
have passed.
Data analysis
All analyses of primary and secondary outcomes 
will be performed according to the intention-to-treat 
principle. The pilot study will also determine the actu-
al event rate in this population. For the pilot study, the 
rates of negativisation of parasite detection by PCR (first 
co-primary outcome) in the benznidazole will be com-
pared to the placebo groups. Logistic regression will be 
performed for the rate of negativisation at two years of 
follow-up. The second co-primary outcome, the differ-
ence in parasite load between the two treatment groups 
at two years of follow-up, will be tested using analysis of 
variance techniques at a 2-sided α of 0.01.
For the full-scale study, the primary analyses will 
compare the time to the first occurrence of any ele-
ment of the primary composite outcome. Patients lost 
to follow-up will be censored at the last time of obser-
vation. Cox proportional hazards model will be used to 
investigate the influence of important confounders and 
prognostic factors. A sensitivity analysis will be per-
formed in patients with prior SVT, previous insertion of 
pacemaker or defibrillator, thromboembolic phenomena 
or heart failure hospitalisation. A prespecified subgroup 
analysis based on the severity of chronic chagasic cardi-
omyopathy (CCC) at admission will also be performed. 
Severity of CCC will be graded according to the recently 
developed Rassi score (Rassi et al. 2006).
Trial progress
Recruitment was initiated in November of 2004 and 
currently includes 42 centres in Argentina, Bolivia, Bra-
zil and Colombia. As of 18 June 2009, over 1,600 patients 
have been enrolled. The overall cumulative rate of drug 
interruptions is nearly 15%, with approximately 6% of 
these patients restarting the assigned treatment.
In conclusion, the BENEFIT trial addresses the un-
answered question of whether etiologic treatment is ben-
eficial for patients already presenting with clinical man-
ifestations of Chagas heart disease. The randomised, 
controlled format of this study constitutes the best tool 
to provide evidence to support any therapeutic decision.
Some might wonder why this trial did not focus on 
the more prevalent population of chagasic patients, i.e., 
those with the indeterminate form of chronic Chagas 
disease. The very long-lasting and unpredictable course 
of this form of the disease makes any study in this pa-
tient population difficult. A more prolonged follow-up 
period in a larger sample size would be required to get 
a sufficient number of hard clinical events to reasonably 
test any hypothesis. However, if the BENEFIT trial suc-
ceeds in showing that trypanocidal therapy effectively 
improves the clinical course of patients with overt cardi-
omyopathy, we could sensibly extrapolate that etiologic 
treatment might also protect patients with the indetermi-
nate form of chronic Chagas disease.
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